Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Resolution, and Perioperative Management

Miguel A. Escobar, MD, Allison P. Wheeler, MD, Steven R. Lentz, MD PhD, Wan Hui Ong Clausen, PhD, David Cooper

Blood (2019) 134 (Supplement_1): 3635.

https://doi.org/10.1182/blood-2019-124889

Published: 2019

Journal Articles

VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD

Ferdows Atiq, Lisette M. Schütte, MD, Agnes E.M. Looijen, Bsc, Johan Boender, MD, Moniek P.M. de Maat, PhD, Marieke J.H.A. Kruip, MD PhD, Frank W.G. Leebeek, MD PhD

Blood (2019) 134 (Supplement_1): 1116.

https://doi.org/10.1182/blood-2019-123634

Published: 2019

Journal Articles

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Bhaskar Vemu, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, John G. Quigley, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Jeremy Johnson, PharmD, PhD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3310.

https://doi.org/10.1182/blood-2019-132216

Published: 2019

Journal Articles

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2018) 132 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2018-99-117566

Published: 2018

Journal Articles

Striking Difference in Iron Utilization between Oral and Intravenous Iron in Various Anemias and Hemochromatosis

Annelies J. Van Vuren, MD, Joannes J.M. Marx, Emeritus Professor, Richard van Wijk, PhD, Eduard J. van Beers, MD PhD

Blood (2018) 132 (Supplement 1): 2338.

https://doi.org/10.1182/blood-2018-99-113030

Published: 2018

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD

Blood (2017) 130 (Supplement 1): 703.

https://doi.org/10.1182/blood.V130.Suppl_1.703.703

Published: 2017

Journal Articles

Results of the First American Prospective Study of IV Iron in Oral Iron Intolerant Iron Deficient Gravidas

Michael Auerbach, MD, Samuel Smith, MD, Stephanie James, MD

Blood (2016) 128 (22): 1277.

https://doi.org/10.1182/blood.V128.22.1277.1277

Published: 2016

Journal Articles

Pretransplantation Myeloablative Conditioning Regimen with Intravenous Busulfan Dose Adjustment for Older Patients with Hematologic Malignancies

Sabine Fürst, MD, Jean El Cheikh, MD PhD, Bénédicte Devictor, MD, Sandra Cournier, Angela Granata, MD, Samia Harbi, MD, Raynier Devillier, MD PhD, Faezeh Legrand, MD, Stefania Bramanti, MD, Claude Lemarie, PharmD, Jean Pierre Weiller, MD, Catherine Faucher, MD, Christian Chabannon, MD PhD, Borje S. Andersson, MD PhD, Didier Blaise, MD PhD

Blood (2016) 128 (22): 5751.

https://doi.org/10.1182/blood.V128.22.5751.5751

Published: 2016

Journal Articles

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Daniel Kobrinski, DO, Tulio E. Rodriguez, MD, Scott E. Smith, MD PhD, Stephanie B. Tsai, MD MA, Zeina Al-Mansour, MD, Mala Parthasarathy, MS, Patrick J. Stiff, MD

Blood (2016) 128 (22): 5795.

https://doi.org/10.1182/blood.V128.22.5795.5795

Published: 2016

Journal Articles

TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease

Sandip Panicker, PhD, Christa Drucker, Sami Hussain, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 94.

https://doi.org/10.1182/blood.V128.22.94.94

Published: 2016

Journal Articles

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Unresponsive to Oral Iron Therapy

Jacquelyn M. Powers, MD, Mark P. Shamoun, MD, Timothy L. McCavit, MD, Leah Adix, CCRP, George R. Buchanan, MD

Blood (2015) 126 (23): 4552.

https://doi.org/10.1182/blood.V126.23.4552.4552

Published: 2015

Journal Articles

Safety and Efficacy of Rapid (one hour) Single Intravenous Dose Low Molecular Weight Iron Dextran for Treatment of Oral Iron Intolerant Maternal Iron Deficient Anemia

Michael Auerbach, MD, Lilee Wong, MD, Jessica McClintock, MD, Steven Lenowitz, MD, Nicola London, MD, Sarah Auerbach, BBA, Samuel Smith, MD

Blood (2015) 126 (23): 3356.

https://doi.org/10.1182/blood.V126.23.3356.3356

Published: 2015

Journal Articles

Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

Judith Trotman, MBChB, Peter J. Shaw, MBBS, MA, FRACP, Campbell Tiley, MBBS,FRACP, FRCPA, Sundra Ramanathan, MBBS FRCPA FRACP, Andrew P Grigg, MBBS MD, Stephen Robert Larsen, MBBS PhDFRCPA FRACP, Peter Presgrave, MBBS, PhD FRACP, FRCPA, Yiu-Lam Kwan, MBBS, FRACP, FRCPA, Elizabeth Newman, RN, Christa Nath, BSC (Hons), PhD

Blood (2015) 126 (23): 4314.

https://doi.org/10.1182/blood.V126.23.4314.4314

Published: 2015

Journal Articles

Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results

Blood (2015) 126 (23): 4376.

https://doi.org/10.1182/blood.V126.23.4376.4376

Published: 2015

Journal Articles

Safety and Efficacy of Total Dose Infusion of Low Molecular Weight (LMW) Iron Dextran in a Large Population of Anemic Patients Across a Broad Spectrum of Diagnoses Associated with Iron Lack

Tahir Mehmood, MD, Khine Swe, MD, Gopimohan Das, MD, Aysegul Gozu, MD MPH, Michael Auerbach, MD, Sein Aung, MD

Blood (2014) 124 (21): 4028.

https://doi.org/10.1182/blood.V124.21.4028.4028

Published: 2014

Journal Articles

CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure

Ravi Vij, MD, Vera Hars, MS, William Blum, MD, Tsiporah B. Shore, Aaron P. Rapoport, MD, Thomas C. Shea, MD, Eva Hoke, Richard M. Stone, MD, Paula Friedman, Kouros Owzar, PhD, Steven M. Devine, MD

Blood (2014) 124 (21): 543.

https://doi.org/10.1182/blood.V124.21.543.543

Published: 2014

Journal Articles

The Clinical and Therapeutic Drug Monitoring of Oral and Intravenous Busulfan in Patients with Acute Leukemia That Underwent to Stem Cell Transplantation with a Test Dose of Busulfan

Iracema Esteves, PhD, Juliana F Fernandes, MD, Andreza Feitosa Ribeiro, MD PhD, Fabio P S Santos, MD, Ricardo Helman, MD, Claudio Castro Junior, MD, Vinicius R. P. Mattos, MD, Andrea Tiemi Kondo, MD, Adriana Seber, MD, Jose Salvador Rodrigues Oliveira, PhD, José Carlos Barros, MD PhD, Vergilio Antonio Renzi Colturato, MD, Nelson Hamerschlak, MD PhD, Fabio Rodrigues Kerbauy, PhD

Blood (2014) 124 (21): 5841.

https://doi.org/10.1182/blood.V124.21.5841.5841

Published: 2014

Journal Articles

Evaluation of Serum Oxidative Stress Indices Following Intravenous Iron Delivery in Women with Iron Deficiency Anemia

James Connor, PhD, Angelia Butcher, BS

Blood (2014) 124 (21): 2683.

https://doi.org/10.1182/blood.V124.21.2683.2683

Published: 2014

Journal Articles

PK-Directed Intravenous Busulfan In Combination With High-Dose Melphalan and Bortezomib As Conditioning Regimen For Patients With Multiple Myeloma

Stefan K Barta, MD, MS, MRCP, Amitabha Mazumder, M.D., Jason Carter, MPH, PA-C, Lawrence Almanzar, MPH, Richard Elkind, Ramakrishna Battini, MD, Olga Derman, MD, Noah Kornblum, MD, Xiaonan Xue, Ph.D., Amit Verma, Ira Braunschweig, MD

Blood (2013) 122 (21): 5513.

https://doi.org/10.1182/blood.V122.21.5513.5513

Published: 2013

NARROW

Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Resolution, and Perioperative Management

VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Striking Difference in Iron Utilization between Oral and Intravenous Iron in Various Anemias and Hemochromatosis

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Results of the First American Prospective Study of IV Iron in Oral Iron Intolerant Iron Deficient Gravidas

Pretransplantation Myeloablative Conditioning Regimen with Intravenous Busulfan Dose Adjustment for Older Patients with Hematologic Malignancies

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Unresponsive to Oral Iron Therapy

Safety and Efficacy of Rapid (one hour) Single Intravenous Dose Low Molecular Weight Iron Dextran for Treatment of Oral Iron Intolerant Maternal Iron Deficient Anemia

Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results

Safety and Efficacy of Total Dose Infusion of Low Molecular Weight (LMW) Iron Dextran in a Large Population of Anemic Patients Across a Broad Spectrum of Diagnoses Associated with Iron Lack

The Clinical and Therapeutic Drug Monitoring of Oral and Intravenous Busulfan in Patients with Acute Leukemia That Underwent to Stem Cell Transplantation with a Test Dose of Busulfan

Evaluation of Serum Oxidative Stress Indices Following Intravenous Iron Delivery in Women with Iron Deficiency Anemia

PK-Directed Intravenous Busulfan In Combination With High-Dose Melphalan and Bortezomib As Conditioning Regimen For Patients With Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only